J&J Reports Breakthrough Survival Data for Lung Cancer Therapy at ASCO 2026

Key Facts

1RYBREVANT plus LAZCLUZE combination showed a median overall survival of nearly 3.5 years in patients with atypical EGFR-mutated NSCLC.

In a move reflecting the accelerating progress in targeted oncology treatments, Johnson & Johnson announced positive long-term data from its CHRYSALIS-2 study. The combination of RYBREVANT and LAZCLUZE demonstrated a median overall survival of nearly 3.5 years in patients with atypical EGFR-mutated lung cancer. According to reports, this combination therapy offers prolonged clinical benefit for difficult-to-treat subgroups that have historically faced poor outcomes.

These results arrive amid intensifying competition in the non-small cell lung cancer (NSCLC) market, where J&J competes with giants like AstraZeneca and Pfizer. Reaching the 42-month survival threshold represents a significant clinical milestone compared to historical standards, per market data and expert commentary from the ASCO 2026 conference. Analysts suggest that the success of this pipeline combination could strengthen the company's position in the high-growth specialized medicine sector.

Regarding market performance, JNJ shares were positioned at $147.20 (close May 28, 2026) prior to the full data release. Investors are now looking toward the upcoming U.S. Core PCE Price Index release on May 29 as a broader market catalyst. Traders should monitor key technical levels, with immediate support near $145 and resistance at $152, as the market digests the clinical implications of these findings.